ArticleAMB Express2026
Sustainable valorization of fish viscera into omega-3 rich lipids and their functional validation.
Article in AMB Express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Fish-processing generates substantial viscera waste that is often discarded or sold at negligible prices, representing both an environmental burden and a missed economic opportunity. This study demonstrates the sustainable valorization of Catla catla viscera through green solvent extraction and urea complexation to obtain polyunsaturated fatty acid (PUFA)-rich fractions. Among extraction methods, the autoclave-assisted approach gave the highest lipid yield (16 ± 0.7%), while the classical Bligh & Dyer method preserved the most balanced PUFA profile (20.16%, with EPA 9.47% and DHA 6.82%). Green-solvent modifications (2-MeTHF and ethanol) maintained yields (~ 9.9%) while enhancing ω-3 PUFA recovery to 19.80%. Subsequent urea complexation increased total PUFA from 28.44% to 56.03% and ω-3 fractions to 49.86% at a 6:1 molar ratio. The PUFA-enriched fraction demonstrated measurable in vitro bioactivities, including antioxidant capacity (IC₅₀ < 0.2 mg mL⁻¹), enhanced wound closure of 78.79 ± 3%, and significant immunomodulation (TNF-α reduced to 112.68 pg/mL; TGF-β1 increased to 571.52 pg/mL) at 50% concentration. A preliminary economic estimation suggests that valorization of viscera into PUFA-rich lipids may substantially enhance value compared with raw disposal, although detailed techno-economic analysis and pilot-scale validation are required to confirm feasibility. This dual demonstration of bioactivity and valorization potential highlights viscera-derived lipids as promising nutraceutical and biomedical resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.